Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...
PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...
Expanding the approval to pediatric patients is expected to improve the diagnostic accuracy of echocardiograms. The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A ...
GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...
GE Healthcare today announced important changes to the U.S. product label for Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the ...
The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ultrasound ...
GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a ...
The International Contrast Ultrasound Society supports the label change of GE Healthcare’s ultrasound contrast agent Optison, according to a news release. Optison is used in contrast-enhanced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results